Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma

Empliciti (Elotuzumab) Postmarketing Surveillance in Korean Patients With Multiple Myeloma

This study is a regulatory postmarketing surveillance study for Empliciti with a representative sample of the overall Korean multiple myeloma (MM) population.

Inclusion Criteria:

• Adult participants who have a confirmed diagnosis of Multiple Myeloma (MM)

Exclusion Criteria:

• Participants who use Empliciti for therapeutic indications which are not approved for Empliciti combination therapy in Korea
• Patients in whom treatment with Empliciti (as clarified in the Korean label) is contraindicated

Other protocol defined inclusion/exclusion criteria could apply